TY - JOUR
T1 - Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe [version 3; peer review: 2 approved]
AU - Moreno-Martos, David
AU - Verhamme, Katia
AU - Ostropolets, Anna
AU - Kostka, Kristin
AU - Duarte-Sales, Talita
AU - Prieto-Alhambra, Daniel
AU - Alshammari, Thamir M
AU - Alghoul, Heba
AU - Ahmed, Waheed-Ul-Rahman
AU - Blacketer, Clair
AU - DuVall, Scott
AU - Lai, Lana
AU - Matheny, Michael
AU - Nyberg, Fredrik
AU - Posada, Jose
AU - Rijnbeek, Peter
AU - Spotnitz, Matthew
AU - Sena, Anthony
AU - Shah, Nigam
AU - Suchard, Marc
AU - Chan You, Seng
AU - Hripcsak, George
AU - Ryan, Patrick
AU - Morales, Daniel
N1 - © 2022 Moreno-Martos D et al.
The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA; This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), US National Institutes of Health, US Department of Veterans Affairs, Janssen Research & Development, and IQVIA; The University of Oxford received funding related to this work from the Bill & Melinda Gates Foundation (Investment ID INV-016201 and INV-019257); IDIAPJGol received funding from the Health Department from the Generalitat de Catalunya with a grant for research projects on SARS-CoV-2 and COVID-19 disease organized by the Direcció General de Recerca i Innovació en Salut; DPA receives funding from NIHR Academy in the form of an NIHR Senior Research Fellowship. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award programme, NIHR, United States Department of Veterans Affairs or the United States Government, NHS, or the Department of Health, England; DRM is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z, https://doi.org/10.35802/214588); and DMM is funded by Health Data Research-UK.
PY - 2023/1/10
Y1 - 2023/1/10
N2 - Background: Characterization studies of COVID-19 patients with chronic obstructive pulmonary disease (COPD) are limited in size and scope. The aim of the study is to provide a large-scale characterization of COVID-19 patients with COPD. Methods: We included thirteen databases contributing data from January-June 2020 from North America (US), Europe and Asia. We defined two cohorts of patients with COVID-19 namely a 'diagnosed' and 'hospitalized' cohort. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes among COPD patients with COVID-19. Results: The study included 934,778 patients in the diagnosed COVID-19 cohort and 177,201 in the hospitalized COVID-19 cohort. Observed COPD prevalence in the diagnosed cohort ranged from 3.8% (95%CI 3.5-4.1%) in French data to 22.7% (95%CI 22.4-23.0) in US data, and from 1.9% (95%CI 1.6-2.2) in South Korean to 44.0% (95%CI 43.1-45.0) in US data, in the hospitalized cohorts. COPD patients in the hospitalized cohort had greater comorbidity than those in the diagnosed cohort, including hypertension, heart disease, diabetes and obesity. Mortality was higher in COPD patients in the hospitalized cohort and ranged from 7.6% (95%CI 6.9-8.4) to 32.2% (95%CI 28.0-36.7) across databases. ARDS, acute renal failure, cardiac arrhythmia and sepsis were the most common outcomes among hospitalized COPD patients. Conclusion: COPD patients with COVID-19 have high levels of COVID-19-associated comorbidities and poor COVID-19 outcomes. Further research is required to identify patients with COPD at high risk of worse outcomes.
AB - Background: Characterization studies of COVID-19 patients with chronic obstructive pulmonary disease (COPD) are limited in size and scope. The aim of the study is to provide a large-scale characterization of COVID-19 patients with COPD. Methods: We included thirteen databases contributing data from January-June 2020 from North America (US), Europe and Asia. We defined two cohorts of patients with COVID-19 namely a 'diagnosed' and 'hospitalized' cohort. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes among COPD patients with COVID-19. Results: The study included 934,778 patients in the diagnosed COVID-19 cohort and 177,201 in the hospitalized COVID-19 cohort. Observed COPD prevalence in the diagnosed cohort ranged from 3.8% (95%CI 3.5-4.1%) in French data to 22.7% (95%CI 22.4-23.0) in US data, and from 1.9% (95%CI 1.6-2.2) in South Korean to 44.0% (95%CI 43.1-45.0) in US data, in the hospitalized cohorts. COPD patients in the hospitalized cohort had greater comorbidity than those in the diagnosed cohort, including hypertension, heart disease, diabetes and obesity. Mortality was higher in COPD patients in the hospitalized cohort and ranged from 7.6% (95%CI 6.9-8.4) to 32.2% (95%CI 28.0-36.7) across databases. ARDS, acute renal failure, cardiac arrhythmia and sepsis were the most common outcomes among hospitalized COPD patients. Conclusion: COPD patients with COVID-19 have high levels of COVID-19-associated comorbidities and poor COVID-19 outcomes. Further research is required to identify patients with COPD at high risk of worse outcomes.
KW - COPD
KW - SARS-CoV-2
KW - coronavirus
KW - COVID
KW - epidemiology
U2 - 10.12688/wellcomeopenres.17403.2
DO - 10.12688/wellcomeopenres.17403.2
M3 - Article
C2 - 36845321
SN - 2398-502X
VL - 7
JO - Wellcome Open Research
JF - Wellcome Open Research
M1 - 22
ER -